You are here: Home / News & Events / News / NORD Helps Fund Groundbreaking Study

NORD Helps Fund Groundbreaking Study

A groundbreaking study in the journal Nature Medicine suggests what could become the first effective treatment for the debilitating central nervous system disease known as SCA1.

A groundbreaking study in the journal Nature Medicine suggests what could become the first effective treatment for the debilitating central nervous system disease known as SCA1.  The study was funded by NIH, NORD, the Brain Research Foundation and the National Ataxia Foundation. 

 
Copyright ©2014 NORD - National Organization for Rare Disorders, Inc. All rights reserved.
The following trademarks/registered service marks are owned by NORD: NORD, National Organization for Rare Disorders, the NORD logo, RareConnect. .